Infusional Cancer Chemotherapy: Historical Evolution and Future Development at the Cancer Center of Boston

References

• Sullivan R D, Young C W, Miller E, et al. The clinical effects of the continuous administration of fluorinated pyrimidines (5-fluo-rouracil and 5-fluoro-2′-deoxyuridine). Cancer Chemother Rep 1960; 8: 77–83
   PubMedGoogle Scholar
• Sullivan R D, Miller E, Chryssochoos T, Watkins E. The clinical effects of the continuous and intra-arterial infusion of cancer chemotherapeutic compounds. Cancer Chemother Rep 1962; 16: 499–510
   PubMedGoogle Scholar
• Frei E, III, Canellos G P. Dose: A critical factor in cancer chemotherapy. Am J Med 1980; 69: 585–594
   PubMed Web of Science ®Google Scholar
• Loehrer P J, Sledge G W, Nicaise C, et al. Ifosfamide plus doxorubicin in metastatic adult sarcomas: A multi-institutional phase II trial. J Clin Oncol 1989; 7: 1655–1659
   PubMed Web of Science ®Google Scholar
• Benvenuto J A, Adams S C, Vyas H M, Anderson R W. Pharmaceutical issues in infusion chemotherapy stability and compatibility. Cancer Chemotherapy by Infusion, J Lokich. Precept Press, Chicago 1987
   Google Scholar
• Williams D A, Lokich J. A review of the stability and compatibility of antineoplastic drugs for multiple-drug infusions. Cancer Chemother Pharmacol 1992; 31: 171–181
   PubMed Web of Science ®Google Scholar
• Drewinko B, Yang L Y. Cellular basis for the inefficacy of 5-fluorouracil in human colon carcinoma. Cancer Treat Rep 1985; 69: 1391–1398
   PubMedGoogle Scholar
• Moertel C G, Schutt A J, Reitemeier R J, Hahn R G. A comparison of 5-fluorouracil administered by slow infusion and rapid Injection. Cancer Res 1972; 32: 2717–2719
   PubMed Web of Science ®Google Scholar
• Lokich J J, Bothe A, Fine N, Perri J. Phase I study of protracted venous infusion of 5-fluorouracil. Cancer 1981; 48: 2565–2568
   PubMed Web of Science ®Google Scholar
• Lokich J J, Moore C. Chemotherapy associated palmar-plantar erythrodysesthesia syndrome. Ann Intern Med 1984; 101: 789–800
   PubMed Web of Science ®Google Scholar
• Milano G. 5-Fluorouracil infusional schedules. J Infus Chemother 1992; 2: 160–163
   Google Scholar
• Ansfield F J, Schroeder J M, Curreri A R. A preliminary comparison of 5-fluoro-2′deoxyuridine administered by rapid daily intravenous injections and by slow continuous infusion. Cancer Chemother Rep 1962; 16: 389–390
   PubMedGoogle Scholar
• Lokich J J, Sonneborn H, Paul S, Zipoli T. Phase I study of continuous venous infusion of floxuridine (5-FUdR) chemotherapy. Cancer Treat Rep 1983; 67: 791–793
   PubMedGoogle Scholar
• Kelvin F M, Gramm H F, Cluck L W, Lokich J J. Radiologic manifestations of small bowel toxicity due to floxuridine therapy. Am J Radiat 1986; 146: 39–43
   Web of Science ®Google Scholar
• Reitemier R J, Moertel C G, Hahn R G. Comparison of 5-fluorouracil and 2′deoxy-5-fluorouridine in treatment of patients with advanced adenocarcinoma of the colon or rectum. Cancer Chemother Rep 1965; 44: 39–43
   PubMedGoogle Scholar
• Lokich J J, Curt G. A phase I and pharmacology study of continuous infusion low-dose methotrexate administration. Cancer 1985; 56: 2391–2394
   PubMed Web of Science ®Google Scholar
• Lokich J J. Phase I–II study of c/j-diamminedichloroplatinum (II) administered by constant 5-day infusion. Cancer Treat Rep 1980; 64: 905–908
   PubMedGoogle Scholar
• Lokich J J, Zipoli T E. Phase I study of protracted infusion of cisplatin. Cancer Drug Deliv 1984; l(3)247–250
   Google Scholar
• Lokich J J, Zipoli T, Greene R, Paul S, Sonneborn H, Moore C. Protracted low-dose cis-platin infusion in advanced colorectal cancer. Caner Treat Rep 1986; 70: 523–524
   PubMedGoogle Scholar
• Bedini A V, Tavecchio L, Milani F, et al. Prolonged venous infusion of cisplatin and concurrent radiation therapy for lung carcinoma. Cancer 1991; 67: 357–362
   PubMed Web of Science ®Google Scholar
• Merlano M, Vitale V, Rosso R, et al. Treatment of advanced squamous-cell carcinoma of the head and neck with alternating chemotherapy and radiotherapy. N Engl J Med 1992; 327: 1115–1121
   PubMed Web of Science ®Google Scholar
• Lokich J J, Anderson N, Bern M, Zipoli T, Gonsalves L, Moore C. Infusional carboplatin: Phase I studies of 5 day and 14 day infusions. Cancer 1991; 68: 68–71
   PubMed Web of Science ®Google Scholar
• Martinez J A, Martin G, Sanz G F, et al. A phase II trial of carboplatin infusion in high-risk acute nonlymphoblastic leukemia. J Clin Oncol 1991; 9: 39–43
   PubMed Web of Science ®Google Scholar
• Smit Ef, Willemse P HB, Sleijfer D T, et al. Continuous infusion carboplatin on a 21-day schedule. A phase I and pharmacokinetic study. J. Clin Oncol 1991; 9: 100–110
   Web of Science ®Google Scholar
• Lokich J. Alkylating agents with infusional schedules of delivery. J Infus Chemother 1991; 1: 17–23
   Google Scholar
• Teicher B A, Holden S A, Eder J P, et al. Influence of schedule on alkylating agent cytotoxicity in vitro and in vivo. Cancer Res 1989; 49: 5994–5998
   PubMed Web of Science ®Google Scholar
• Lokich J J, Bothe A. Phase I study of continuous infusion cyclophosphamide for protracted durations. Cancer Drug Deliv 1984; 4: 329–332
   Google Scholar
• Lokich J, Anderson N, Bern M, et al. Infusional cyclophosphamide for resistant lymphoma. J Infusional Chemo 1993; 3: 184–186
   Google Scholar
• Engelsman E, Klijn J CM, Rubens R D, et al. Classical CMF versus a 3-weekly intravenous CMF schedule in postmenopausal patients with advanced breast cancer. Eur J Cancer 1991; 27: 966–970
   PubMed Web of Science ®Google Scholar
• Lokich J J, Anderson N, Bern M, Moore C. Ifosfamide continuous infusion without mesna: A phase I trial of a 14-day cycle. Cancer 1991; 67: 883–885
   PubMed Web of Science ®Google Scholar
• Lokich J J, Egorin M, Cohen B, Bern M, Zipoli T, Moore C. A phase I study of thiotepa administered by short-term and protracted continuous intravenous infusion. Cancer 1989; 63: 46–50
   PubMed Web of Science ®Google Scholar
• Lokich J J, Zipoli T E, Sonneborn H, Paul S, Phillips D. Streptozotocin for metastatic malignant melanoma. Am J Clin Oncol 1985; 3(5)710–717
   Google Scholar
• Lokich J J, Perri J, Fine N, Bothe A. Mitomycin C; Phase I study of a constant infusion ambulatory treatment schedule. Am J Clin Oncol Cancer Trials 1982; 5: 443–447
   PubMed Web of Science ®Google Scholar
• Lokich J J, Bothe A, Zipoli T, Green R, Sonneborn H, Paul S, Phillips D. Constant infusion schedule for adriamycin: A phase I–II clinical trial of a 30-day schedule by ambulatory pump delivery system. J Clin Oncol 1983; l(l)24–28
   Google Scholar
• Sweatman T W, Lokich J J, Israel M. Clinical pharmacology of continuous infusion doxorubicin. Ther Drug Monit 1989; 11: 3–9
   PubMed Web of Science ®Google Scholar
• Legha S. Infusional schedules for antitumor antibiotics. J Infus Chemother 1991; 1: 24–27
   Google Scholar
• Slevin M L, Clark P L, Joel S P, et al. A randomized trial to evaluate the effect of schedule on the activity of etoposide in small cell lung cancer. J Clin Oncol 1989; 7: 1333–1340
   PubMed Web of Science ®Google Scholar
• Lokich J J, Corkery J. Phase I study of VP-16–213 administered as a continuous five day infusion. Cancer Treat Rep 1981; 65(6–10)887–889
   PubMedGoogle Scholar
• Lokich J. Multi drug infusional chemotherapy using admixtures. Continuous Infusion Chemotherapy and Concomitant Radiation Therapy, J Rosenthal, M Rotman. Plenum Press, New York 1986
   Google Scholar
• Lokich J J, Zipoli T E, Perri J, Bothe A. Protracted vinblastine infusion phase I–II study in malignant melanoma and other tumors. Am J Clin Oncol (CCT) 1984; 7: 551–553
   PubMed Web of Science ®Google Scholar
• Lokich J J, Zipoli T E, Green R. Infusional cisplatin plus cyclophosphamide in advanced ovarian cancer. Cancer 1986; 58: 2389–2392
   PubMed Web of Science ®Google Scholar
• Anderson N, Lokich J, Moore C. Mitomycin C (MMC) for treatment of measurable colorectal carcinoma (CRC) resistant to 5fluorouracil (FU). Proc ASCO 1992; 11: 191, (abstract 579)
   Google Scholar
• Lokich J, Auerback M, Smith L, et al. A comparative trial of three schedules for single-agent doxorubicin in advanced breast cancer: An aborted investigation. J Infus Chemother 1992; 2: 185–188
   Google Scholar
• Schell F C, Yap H Y, Hortobagyi N, Issell B, Esparza L. Phase II study of VP16–213 (etoposide) in refractory metastatic breast carcinoma. Cancer Chemother Pharmacol 1982; 7: 223–225
   PubMed Web of Science ®Google Scholar
• Seifert P, Baker L H, Reed M L, Vaitkevicius V K. Comparison of continuously infused 5fluorouracil with bolus injection in treatment of patients with colorectal adenocarcinoma. Cancer 1975; 36: 123–128
   PubMed Web of Science ®Google Scholar
• Lokich J J, Ahlgren J, Gullo J, et al. A prospective randomized comparison of continuous infusional 5-fluorouracil with a conventional bolus schedule in metastatic colorectal cardinoma: A Mid Atlantic Oncology Program Study. J Clin Oncol 1989; 7: 425–432
   PubMed Web of Science ®Google Scholar
• Lokich J, Byfield J. Combined Modality Radiation and Infusional Chemotherapy. Precept Press, Chicago 1991
   Google Scholar
• Rich T A, Lokich J J, Chaffey J T. A pilot study of protracted venous infusion of 5fluorouracil and concomitant radiation therapy. J Clin Oncol 1985; 3: 402–406
   PubMed Web of Science ®Google Scholar
• Lokich J J, Chaffey J, Nedptune W. Concomitant 5fluorouracil infusion and high dose radiation therapy for stage III non small cell lung cancer. Cancer 1989; 64: 1021–1025
   PubMed Web of Science ®Google Scholar
• Lokich J J, Shea M, Chaffey J. Sequential infusional 5fluorouracil followed by concomitant radiation therapy for tumors of the esophagus and gastroesophageal junction. Cancer 1987; 60: 275–279
   PubMed Web of Science ®Google Scholar
• Forastiere A A. Treatment of locoregional esophageal cancer. Semin Oncol 1992; 19: 57–63
   PubMed Web of Science ®Google Scholar
• Anderson N, Lokich J, Bern M, Wallach S, Moore C, Williams D, Umprain V. Combined floxuridine and cisplatin in a fourteen day infusion. Cancer 1988; 62: 2302–2312
   Google Scholar
• Anderson N, Lokich J J, Bern M, Wallach S, Moore C, Williams D, Umprain V. Combined Sfluorouracil and floxuridine administered as a 14-day infusion. Cancer 1989; 63: 825–827
   PubMed Web of Science ®Google Scholar
• Lokich J J, Zipoli T, Moore C, Sonneborn H, Paul S, Greene R. Doxorubicin/vinblastine and doxorubicin/cyclophosphamide combination chemotherapy by continuous infusion. Cancer, 58: 1020–1023
   PubMed Web of Science ®Google Scholar
• Lokich J J, Anderson N, Bern M, Wallach S, Moore C, Williams D. Etoposide admixed with cisplatin. Cancer 1989; 63: 818–821
   PubMed Web of Science ®Google Scholar
• Bern M M, Lokich J J, Anderson N E, Lebine H L, Zipoli H. Combination chemotherapy using etoposide and platinum or carboplatin for metastatic carcinoma to brain. J Infus Chemother, (in press)
   Google Scholar
• Lokich J, Schulz J, Rosenthal D J, Fryer J, Alt D. Etoposide plus cisplatin by 72 hour infusion for non small cell lung cancer. J Infus Chemother, (in press)
   Google Scholar
• Lokich J, Anderson N, Bern M, Zipoli T, Gonsalves L, Moore C. Etoposide plus carboplatin admixture: Phase I study of five or seven day continuous infusion. Am J Clin Oncol 1992; 15(2)
   Google Scholar
• Lokich J J, Zipoli T, Anderson N, et al. Pilot study of ambulatory infusional ifosfamide admixed with carboplatin. Cancer, (in press)
   Web of Science ®Google Scholar
• Lokich J J, Bern M, Anderson N, Wallach S, Moore C, Beau-Champ K, Williams D. Cyclophosphamide, methotrexate, and 5-fluorouracil in a three-drug admixture. Cancerf 1989; 63: 822–821
   PubMed Web of Science ®Google Scholar
• Lokich J, Moore C, Anderson N, Bern M. Infusion of floxuridine plus etoposide plus cisplatin in human malignancies. Eur J Cancer 1991; 27: 1593–1596
   PubMed Web of Science ®Google Scholar
• Dreyfuss Al, Clark J R, Wright J E, et al. Continuous infusion high-dose leucovorin with 5-fluorouracil and cisplatin for untreated stage IV carcinoma of the head and nack. Ann Intern Med 1990; 112: 167–172
   PubMed Web of Science ®Google Scholar
• Lokich J, Anderson N, Bern M, Coco F, Zipoli T, Moore C. Multi-drug infusion of 5fluorouracil, leucovorin and platinum (PLF). An analysis of leucovorin dosing. J Infus Chemother, (in press)
   Google Scholar
• Lynch T J, Skarin A, Elias A D, Kass F, Shulman L, Frei E, III. A phase II trial of PFL in advanced NSCLC. Proc ASCO 1991; 10: 259, (abstract 894)
   Google Scholar
• Anderson N, Lokich J, Moore C, et al. Treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) with infusional carboplatin (C), ifosfamide (I), mesna (M) and etoposide (E). Proc ASCO 1991; 10: 269, (abstract 935)
   Google Scholar
• Lokich J J, Phillips D, Greene R, Paul S, Sonneborn H, Zipoli T E, Curt G. 5Fluorouracil and methotrexate administered simultaneously as a continuous infusion: A phase I study. Cancer 1985; 56: 2395–2398
   PubMed Web of Science ®Google Scholar
• Lokich J J, Anderson N, Bern M, Wallach S, Moore C, Williams D. A phase I clinical trial of combined fluoropyrimidines with leucovorin in a 14-day infusion. Cancer 1989; 63: 233–237
   PubMed Web of Science ®Google Scholar
• Lokich J J, Anderson N, Bern M, Coco F, Zipoli T, Moore C, Gonsalves L. Dual modulation of 5fluorouracil using leucovorin and hydroxyurea. Cancer 1991; 68: 744–746
   PubMed Web of Science ®Google Scholar
• Anderson N R, Lokich J J. Controversial issues in 5-fluorouracil infusion use. Cancer 1992; 70: 998–1002
   PubMed Web of Science ®Google Scholar
• Anderson N. Black holes and billed charges: An analysis of infusional therapy costs. J Infus Chemother 1992; 2: 94–96
   Google Scholar
• Abeloff M D, Beveridge R A, Donehower R C, et al. Sixteen-week dose intense chemotherapy in the adjuvant treatment of breast cancer. J Natl Cancer Inst 1990; 82: 570–574
   PubMed Web of Science ®Google Scholar
• Lieberman R. Clinical pharmacokinetics of suramin therapy. J Infus Chemother 1992; 2: 177–184
   Google Scholar